Fosun Pharma: Subsidiary’s drug approved for clinical trials

2026-04-01 23:51:19

People’s Finance News, March 31, 3月31日, Fosun Pharmaceutical (600196) announced on March 31 that its controlling subsidiary, Fosun Hanlin, received an approval from the National Medical Products Administration agreeing to the use of HLXTE-HAase02 (i.e., recombinant human hyaluronidase injection) to promote the diffusion and absorption of drugs for subcutaneous injection or subcutaneous infusion, to carry out a Phase I clinical trial. On the same day, the company also announced that its controlling subsidiary, Fosun Pharmaceutical Industry, received an approval from the National Medical Products Administration agreeing to the use of FXB0871 to conduct a clinical trial for locally advanced or metastatic solid tumors.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes